BCC 2023 | Is there a potential benefit of intermediate duration of adjuvant endocrine therapy?

Jens Huober, MD, Ulm University Hospital, Ulm, Germany, discusses the potential benefit of intermediate duration of adjuvant endocrine therapy, where there are patients who will benefit from longer endocrine treatment beyond five years, and it is very vital to assess the risk of relapse. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.